2010309E21Rik Activators
The process of identifying these activators commences with a meticulous approach involving high-throughput screening (HTS). In this phase, extensive libraries of chemical entities are meticulously tested in cellular assays designed to detect upregulation of the gene's activity. These assays are ingeniously constructed by linking the gene's promoter to a reporter system, such as fluorescent or luminescent markers, that can indicate the gene's expression levels. A compound that can activate the 2010309E21Rik gene will lead to an increased signal from the reporter, making it possible to quantify the degree of activation. After potential activators are identified through HTS, they undergo rigorous validation assays to ascertain their specificity and efficacy in upregulating the 2010309E21Rik gene. Quantitative polymerase chain reaction (qPCR) is employed to measure the mRNA levels of the gene after interaction with these chemical compounds, providing quantitative data on their influence over gene expression at the transcriptional stage. A significant elevation in mRNA levels post-application is indicative of transcriptional activation.
Additionally, the activation's impact on protein synthesis is evaluated using the Western blot technique. This method allows for the detection and quantification of the protein encoded by the 2010309E21Rik gene. A concordant increase in both mRNA and protein levels upon interaction with a compound is a compelling confirmation of the compound's role as an activator. These validation methods are not only crucial for confirming the results of the initial HTS but also provide a detailed understanding of the mechanism by which these activators exert their effect on the gene's expression.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Ionomycin, free acid | 56092-81-0 | sc-263405 sc-263405A | 1 mg 5 mg | $96.00 $264.00 | 2 | |
Ionomycin is a calcium ionophore that increases intracellular calcium concentrations. This elevation in calcium may activate calcium-dependent protein kinases or other calcium-binding proteins, which could indirectly enhance the activity of 2010309E21Rik if it is calcium-dependent. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA is a diacylglycerol (DAG) analog that activates protein kinase C (PKC). PKC phosphorylates target proteins, which may lead to the enhancement of 2010309E21Rik activity if it is regulated by PKC-mediated phosphorylation. | ||||||
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $66.00 $325.00 $587.00 $1018.00 | 28 | |
Retinoic acid acts by binding to its nuclear receptors (RARs and RXRs), which regulate gene expression. If 2010309E21Rik is under the regulatory control of genes responsive to retinoic acid, its activity could be indirectly enhanced. | ||||||
Adenosine 3′,5′-cyclic monophosphate | 60-92-4 | sc-217584 sc-217584A sc-217584B sc-217584C sc-217584D sc-217584E | 100 mg 250 mg 5 g 10 g 25 g 50 g | $116.00 $179.00 $265.00 $369.00 $629.00 $1150.00 | ||
Dibutyryl cAMP is a cell-permeable cAMP analog that activates PKA. This activation can lead to the phosphorylation of proteins and potentially enhance the activity of 2010309E21Rik if it is a PKA substrate. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
EGCG is known to inhibit certain protein kinases. If 2010309E21Rik is negatively regulated by a kinase that is inhibited by EGCG, its activity could be indirectly enhanced by the reduction of inhibitory phosphorylation. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $165.00 $322.00 $570.00 $907.00 $1727.00 | 7 | |
S1P activates S1P receptors, which can trigger intracellular signaling cascades including the PI3K/Akt pathway. If 2010309E21Rik activity is enhanced by PI3K/Akt signaling, S1P could indirectly increase its activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is an inhibitor of PI3K. If 2010309E21Rik is part of a signaling cascade that is negatively regulated by PI3K activity, inhibition by LY294002 could remove this negative regulation and enhance 2010309E21Rik activity. | ||||||
Oligomycin A | 579-13-5 | sc-201551 sc-201551A sc-201551B sc-201551C sc-201551D | 5 mg 25 mg 100 mg 500 mg 1 g | $179.00 $612.00 $1203.00 $5202.00 $9364.00 | 26 | |
Oligomycin inhibits ATP synthase, leading to increased intracellular ADP. If 2010309E21Rik requires ADP or is regulated by sensors of cellular energy status, oligomycin might enhance the activity of 2010309E21Rik indirectly. | ||||||
Zinc | 7440-66-6 | sc-213177 | 100 g | $48.00 | ||
Zinc chloride can modulate the activity of various zinc finger proteins and metalloenzymes. If 2010309E21Rik possesses a zinc-binding domain or is regulated by zinc-sensitive proteins, ZnCl2 may enhance its activity. | ||||||
NAD+, Free Acid | 53-84-9 | sc-208084B sc-208084 sc-208084A sc-208084C sc-208084D sc-208084E sc-208084F | 1 g 5 g 10 g 25 g 100 g 1 kg 5 kg | $57.00 $191.00 $302.00 $450.00 $1800.00 $3570.00 $10710.00 | 4 | |
NAD+ is a coenzyme involved in redox reactions. If 2010309E21Rik is part of pathways that are regulated by NAD+/NADH ratio or if it has ADP-ribosyltransferase activity, NAD+ could enhance its activity. | ||||||